Nasdaq
LumiraDx Receives Notice From Nasdaq Over Missed Listing Requirement
The UK-based point-of-care diagnostics company received the letter because its common shares on the Nasdaq closed below $1 for 30 consecutive trading days.
AnPac Bio Receives Nasdaq Delisting Notice
The Chinese cancer diagnostics firm plans to appeal the decision, which is related to a requirement that the firm maintain a minimum $2.5 million stockholders' equity.
Genetron Regains Compliance With Nasdaq Listing Requirement
The Chinese cancer molecular profiling firm had previously failed to meet the Nasdaq's minimum bid price requirement.
Sema4 Receives Nasdaq Noncompliance Warning, Will Return $42M Under Payor Lawsuit Settlement
The company's stock price had been below $1 per share for 30 trading days prior to the notice, which Sema4 received Dec. 28.
Centogene Gets Nasdaq Non-Compliance Notice
The company has 180 days from the date of the notice to regain compliance with the listing requirement, during which time it will continue to trade on the exchange.
Sep 27, 2022
AnPac Bio Inks Deal for $3.7M Investment
Sep 12, 2022
AnPac Bio Receives Nasdaq Delisting Determination
Aug 30, 2022
T2 Biosystems Regains Nasdaq Listing Requirements
Mar 28, 2022
AnPac Bio Receives Nasdaq Delisting Notice
Jan 25, 2022
AnPac Bio Warned by Nasdaq Over Listing Requirement
Sep 16, 2021
Hong Kong-Based Prenetics to go Public via SPAC
Jan 19, 2021